What Happened?
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after The U.S. Food and Drug Administration approved Eli Lilly’s once-weekly basal insulin, Onswik, for adults with type 2 diabetes, giving patients an alternative to daily long-acting insulin shots. According to Reuters, Lilly said Onswik — chemically known as insulin efsitora alfa-gobe — is intended to be used with diet and exercise to help control high blood sugar and could cut the number of injections by more than 300 per year versus once-daily basal insulin. The company said the drug will be available in the U.S. in the coming months as a pre-filled KwikPen in 500 units/mL and 1,000 units/mL concentrations. Reuters reported that approval was based on late-stage trials enrolling more than 3,400 adults across four studies, in which Onswik met its main goal by showing A1C reductions that were not inferior to daily basal insulin glargine. Lilly said the therapy should not be used in type 1 diabetes because of a higher risk of severe hypoglycemia; Onswik was already approved in Europe, Japan, and Mexico. A once-weekly insulin approval strengthens Lilly’s diabetes franchise by lowering the dosing burden that often limits adherence — a commercial edge that can matter as it competes with rivals such as Novo Nordisk in basal insulin.
The shares were trading at $1,192, up 3.4% from the previous close.
Is now the time to buy Eli Lilly? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Eli Lilly’s shares are not very volatile and have only had 7 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 8 months ago when the stock gained 10% on the news that the company reported fourth-quarter 2025 results that beat Wall Street expectations and issued an upbeat forecast for 2026, driven by high demand for its weight-loss drugs. The pharmaceutical company's revenue grew 42.6% year-over-year to $19.29 billion, surpassing analysts' estimates. Adjusted earnings per share came in at $7.54, which was also well above expectations. This strong performance was fueled by soaring sales of its popular weight-loss and diabetes drugs, Zepbound and Mounjaro. Looking ahead, Eli Lilly provided a positive outlook for 2026, forecasting revenue of $81.5 billion at the midpoint and adjusted earnings per share of $34.25 at the midpoint. Both projections were higher than what analysts had predicted.
Eli Lilly is up 10.3% since the beginning of the year, and at $1,192 per share, it is trading close to its 52-week high of $1,280 from August 2026. Investors who bought $1,000 worth of Eli Lilly’s shares 5 years ago would now be looking at an investment worth $5,144.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.